← ANALYST RATINGS · TIPRANKS
Crescent Biopharma (CBIO): analyst forecast and price target
Analyst consensus
Strong Buy5 Buy0 Hold0 Sell
Ratings of 5 analysts in the last 3 months12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $30.80, the highest $36.00, the lowest $27.00. The average is +160.1% from the last price of $11.84.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Biren Amin★★★★★★★★★★#1671 · hits 46% · avg +7.6% | Piper Sandler | $35.00 | Buy | +195.6% | Reiterated | 16.10.26on TipRanks 08:08 | −4.0% | ↗ |
| Stephen Willey★★★★★★★★★★#1608 · hits 45% · avg +8.1% | Stifel Nicolaus | $28.00 | Buy | +136.5% | Reiterated | 16.10.26on TipRanks 07:30 | −4.0% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $13.50 → $12.50−7.4% | Hold | +5.6% | Upgrade | 16.10.26on TipRanks Oct 15 23:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $13.50 → $12.00−11.1% | Hold | +1.4% | Upgrade | 16.10.26on TipRanks Oct 15 23:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $13.50 → $12.00−11.1% | Hold | +1.4% | Reiterated | 16.10.26on TipRanks Oct 15 23:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $13.50 → $11.50−14.8% | Sell | −2.9% | Downgrade | 16.10.26on TipRanks Oct 15 23:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $13.50 → $12.50−7.4% | Hold | +5.6% | Upgrade | 16.10.26on TipRanks Oct 15 23:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $13.50 → $12.50−7.4% | Hold | +5.6% | Reiterated | 16.10.26on TipRanks Oct 15 23:05 | — | |
| Mitchell Kapoor★★★★★★★★★★#1086 · hits 45% · avg +12.2% | H.C. Wainwright | $36.00 | Buy | +204.1% | Upgrade | 06.10.26on TipRanks 06:20 | −3.2%next day −0.3% · 5 days −4.7% | ↗ |
| Charles Zhu★★★★★★★★★★#351 · hits 64% · avg +25.8% | LifeSci Capital | $28.00 | Buy | +136.5% | Reiterated | 05.10.26on TipRanks 10:35 | −3.3%next day −3.2% · 5 days +3.3% | ↗ |
| Robert Driscoll★★★★★★★★★★#1346 · hits 46% · avg +10.6% | Wedbush | $27.00 | Buy | +128.0% | Reiterated | 14.09.26on TipRanks 21:49 | −4.0%next day −8.2% · 5 days −14.9% | ↗ |
| Bradley Canino★★★★★★★★★★#1614 · hits 46% · avg +10.8% | Guggenheim | $35.00 | Buy | +195.6% | Reiterated | 29.04.26on TipRanks Apr 30 07:00 | −12.6%next day +5.8% · 5 days −16.9% | ↗ |
| Phil Nadeau★★★★★★★★★★#1350 · hits 48% · avg +8.7% | TD Cowen | — | Buy | — | Reiterated | 29.04.26on TipRanks 23:45 | +5.8%next day −19.5% · 5 days −21.3% | ↗ |
| Akash Tewari★★★★★★★★★★#649 · hits 57% · avg +13.5% | Jefferies | $35.00 | Buy | +195.6% | Reiterated | 05.12.25on TipRanks 11:50 | +0.4%next day +1.1% · 5 days +8.4% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Crescent Biopharma
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $27.67 at a price of $14.59 (+89.6%); now: $30.80 at $11.84 (+160.1%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 7 | 7 | 6 | 3 | 5 |
| Buy | 6 | 7 | 2 | 1 | 1 | 1 |
| Hold | 0 | 1 | 3 | 3 | 2 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.67 (from $-0.85 to $-0.53). Last quarter: $-0.74.
Sales
Next quarter’s sales estimate — $0M (from $0M to $2M). Last quarter: $0M.
Best top-analyst consensus in the sector · Healthcare
About Crescent Biopharma
- CEO: Joshua T. Brumm
- Employees: 44
- 300 Fifth Avenue, Waltham, MA, 02451, US
- crescentbiopharma.com
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.
Data from the stock’s TipRanks forecast page, read 18 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗